ARE YOUR PATIENTS ELIGIBLE FOR
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)?
Please see most common responsive mutations below.
Mutations were considered responsive if CFTR activity resulted in a net increase of ≥10% over baseline after
aPresent in ≥0.6% of individuals with CF.2